Ten big challenges ahead, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1 ,
DOI : 10.1186/1471-2334-14-S2-S1
New ARV drugs, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.2 ,
DOI : 10.1186/1471-2334-14-S2-S2
Development of long-acting ARVs, BMC Infect Dis, vol.2014, issue.14 2, p.11 ,
First Line Therapy in 2014, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.3 ,
DOI : 10.1186/1471-2334-14-S2-S3
First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1402 ,
DOI : 10.1186/1471-2334-14-S2-O2
Immune Activation and Collateral Damage in AIDS Pathogenesis, Frontiers in Immunology, vol.4, 2013. ,
DOI : 10.3389/fimmu.2013.00298
Aging with HIV, Current Opinion in HIV and AIDS, vol.9, issue.4, pp.428-435 ,
DOI : 10.1097/COH.0000000000000080
ARV regimen choice and co-morbidities, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.9 ,
DOI : 10.1186/1471-2334-14-S2-S9
URL : http://doi.org/10.1186/1471-2334-14-s2-s9
Statin use in setting of HIV infection, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.10 ,
DOI : 10.1136/bmj.f2610
Transition to Adulthood and Antiretroviral Adherence Among HIV-Positive Young Black Men Who Have Sex With Men, American Journal of Public Health, vol.105, issue.4, pp.1-7, 2014. ,
DOI : 10.2105/AJPH.2014.301905
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358185
ART for prevention: opportunities, challenges and predictions, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.7 ,
DOI : 10.1186/1471-2334-14-S2-S7
URL : http://doi.org/10.1186/1471-2334-14-s2-s7
Implementation of TasP: challenges and opportunities, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.8 ,
DOI : 10.1186/1471-2334-14-S2-S8
Update on HIV reservoirs, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.18 ,
DOI : 10.1186/1471-2334-14-S2-S18
Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials, Human Vaccines & Immunotherapeutics, vol.6, issue.4, pp.790-799 ,
DOI : 10.4161/hv.23202
Gene therapy and bone marrow transplantation, BMC Infect Dis, vol.2014, issue.14 2, p.19 ,
Next-generation LTR-specific Tre-recombinase targets a majority of HIV-1 isolates, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.14018 ,
DOI : 10.1186/1471-2334-14-S2-O18
Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.14019 ,
DOI : 10.1186/1471-2334-14-S2-O19
Differential glycosylation of envelope gp120 affects reactivity with HIV-1 specific antibodies, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1468 ,
DOI : 10.1186/1471-2334-14-S2-P68
Is an HIV vaccine achievable?, BMC Infect Dis, vol.2014, issue.14 2, p.14 ,
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand, New England Journal of Medicine, vol.361, issue.23, pp.3612209-2220, 2009. ,
DOI : 10.1056/NEJMoa0908492
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies, Nature, vol.509, pp.55-62, 2014. ,
Which antibody functions are important for an HIV vaccine? Front Immunol, p.289, 2014. ,
Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIV-discordant couples is associated with higher frequency of CD8+ T cells expressing CD107a and b molecules, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1467 ,
DOI : 10.1186/1471-2334-14-S2-P67
The potential role of HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppressive activity and cytotoxicity in HIV controllers, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1464 ,
DOI : 10.1186/1471-2334-14-S2-P64
URL : https://hal.archives-ouvertes.fr/inserm-00995736
Personalizing humanized mice with cells obtained from an HIV post treatment controller, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1436 ,
DOI : 10.1186/1471-2334-14-S2-P36
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?, Nature Medicine, vol.453, issue.8, pp.866-870, 2009. ,
DOI : 10.1038/nm.1949
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy, Cell, vol.156, issue.4, pp.633-648, 2014. ,
DOI : 10.1016/j.cell.2014.01.052
Optimized production of a safe and efficient gene therapeutic vaccine versus HIV via a linear covalently closed DNA minivector, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.74 ,
DOI : 10.1186/1471-2334-14-S2-P74
In vivo analysis of GenePro, a lentivral therapeutic vaccine, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.2 ,
DOI : 10.1186/1471-2334-14-S2-P2
Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1481 ,
DOI : 10.1186/1471-2334-14-S2-P81
Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study, BMC Infect Dis, vol.2014, issue.2, pp.14-20 ,
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission, Nature Medicine, vol.20, issue.3, pp.296-300, 2014. ,
DOI : 10.1038/nm1431
One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy, J Acquir Immune Defic Syndr, vol.5, issue.7, pp.676-681, 1992. ,
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding, Proceedings of the National Academy of Sciences, vol.110, issue.1, pp.69-78 ,
DOI : 10.1073/pnas.1217609110
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow, Liver International, vol.141, issue.Suppl 1, pp.88-102 ,
DOI : 10.1111/j.1478-3231.2011.02699.x
HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78 ,
DOI : 10.1111/liv.12423
Prise en charge th??rapeutique de l???h??patite??C ?? l???heure des agents antiviraux directs??: vers une ??radication virale, La Revue de M??decine Interne, vol.35, issue.4, pp.219-221, 2014. ,
DOI : 10.1016/j.revmed.2013.12.017
Antiviral treatment of hepatitis C, BMJ, vol.349, issue.jul07 3, p.3308 ,
DOI : 10.1136/bmj.g3308
Managing HCV infection: present and future, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.5 ,
DOI : 10.1186/1471-2334-14-S2-S5
New anti-HCV agents in the pipeline, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.15 ,
DOI : 10.1186/1471-2334-14-S2-S15
URL : https://hal.archives-ouvertes.fr/inserm-00995744
Treatment of hepatitis C in HIV patients in the new DAA era, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.16 ,
DOI : 10.1186/1471-2334-14-S2-S16
Chikungunya infection: six years after, rheumatic morbidity and impaired quality of life persist!, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.21 ,
DOI : 10.1186/1471-2334-14-S2-O21
Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island, BMC Infectious Diseases, vol.14, issue.Suppl 2, pp.14-20 ,
DOI : 10.1186/1471-2334-14-S2-O20